Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug

3 weeks ago 8

Soumya Eswaran

Mon, December 1, 2025 astatine 6:58 AM CST 3 min read

Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. Equities deed a grounds precocious successful the 3rd quarter, fueled by continued gains successful exertion and falling enslaved yields. Easing tariff rhetoric and renewed AI infrastructure investments boosted ample tech stocks. In mid-September U.S. Federal Reserve lowered rates by 25 ground points. Against this backdrop, the money returned -1.78% (net) compared to the Russell 2500 Growth Index’s 10.73% return. Sector positioning and the avoidance of names that bash not conscionable the firm’s strict concern subject led to the underperformance of the money successful the quarter. In addition, delight cheque the fund’s apical 5 holdings to cognize its champion picks successful 2025.

In its third-quarter 2025 capitalist letter, Meridian Growth Fund highlighted stocks specified arsenic Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL). Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is simply a biopharmaceutical company. The one-month instrumentality of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) was 44.78%, and its shares gained 87.41% of their worth implicit the past 52 weeks. On November 28, 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) banal closed astatine $596.98 per share, with a marketplace capitalization of $13.558 billion.

Meridian Growth Fund stated the pursuing regarding Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) successful its 3rd 4th 2025 capitalist letter:

"Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is simply a commercial-stage biopharmaceutical institution focused connected delivering caller therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a non-alcoholic liver illness with a precocious unmet aesculapian need. The banal performed good connected grounds of a precise beardown commercialized motorboat and execution of Rezdiffra, a caller cause therapy that has enactment Madrigal connected an annualized gait for much than $1 cardinal successful caller income this year. With U.S. marketplace penetration successful the azygous digits, the therapy has the imaginable to turn into a multi-billion-dollar blockbuster implicit time. In addition, the institution in-licensed an oral GLP-1 drug, and further therapies successful the pipeline besides amusement committedness of incremental growth. During the period, we trimmed our presumption arsenic the stock terms appreciated, based connected our valuation discipline."

Is Madrigal Pharmaceuticals, Inc. (MDGL) The Most Expensive Stock Insiders Are Dumping In March?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 48 hedge money portfolios held Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) astatine the extremity of the 3rd quarter, up from 47 successful the erstwhile quarter. In the 3rd 4th of 2025, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported nett sales of $287 million, up 35% quarter-over-quarter. While we admit the imaginable of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.